U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT06930651) titled 'A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies' on April 09.
Brief Summary: The goal of this clinical research study is to find the recommended safe dose of TGFBR2 KO CAR27/IL-15 NK cells that can be given to patients with relapsed/refractory disease. The safety and effectiveness of this treatment will also be studied.
Study Start Date: Oct. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Myeloid Malignancies
Intervention:
DRUG: Dexameth...